Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled
into the study (Part A: 2-18; Part B: 7-19). The study has been designed to allow an
investigation of the optimal combination dose and schedule whilst of Osimertinib plus
Anlotinib in patients with EGFRm+, treatment-naïve IIIb/IV Non-Small Cell Lung Cancer (NSCLC)
ensuring the safety of patients with intensive safety monitoring. There are two main parts to
this study; Part A, Combination dose finding and Parts B, Dose expansion.